The Rapid Mood Screener (RMS) is a 6-item, self-administered screening tool that helps clinicians distinguish bipolar I disorder from major depressive disorder in patients presenting with depressive symptoms. Developed by McIntyre and colleagues and published in 2020, the RMS combines three manic-symptom items with three depression-history features and can be completed in under two minutes.
Designed for Depressed Patients
Unlike screeners that ask broadly about lifetime mania, the RMS is built for the specific clinical question that comes up most often: in a patient with depression, is this bipolar I or unipolar?
Very Brief and Patient-Friendly
Six yes/no items take roughly two minutes to complete, which makes the RMS practical for busy primary care visits and telehealth encounters where longer instruments are not feasible.
Strong Validation Performance
The original validation study reported a C-index of 0.87 and, at a cutoff of four endorsed items, sensitivity of 0.88 and specificity of 0.80 for differentiating bipolar I from major depressive disorder.
Captures Bipolar Indicators Beyond Mania
The RMS incorporates depression-history features — such as earlier age of depression onset and prior poor response to antidepressants — that are independently associated with bipolarity and that pure mania screeners miss.
Reduces Misdiagnosis Risk Before Antidepressant Therapy
Identifying a high likelihood of bipolar I before initiating antidepressant monotherapy supports safer prescribing and earlier referral for specialty evaluation.
Primary Care
Used during depression evaluations to flag patients who warrant a more detailed bipolar workup before starting an antidepressant.
Outpatient Psychiatry
Administered at intake or before medication changes in patients with treatment-resistant or recurrent depression, where unrecognized bipolarity is a leading differential consideration.
Telehealth and Digital Behavioral Health
Embedded in pre-visit intake workflows so clinicians arrive at the encounter with a structured signal about diagnostic likelihood.
Integrated Care Settings
Combined with depression and anxiety screeners (PHQ-9, GAD-7) to provide a fuller mood picture in collaborative care programs.
Emergency and Urgent Mental Health
Used as part of a brief mood assessment when patients present with acute depressive symptoms and limited diagnostic history.
The RMS asks the patient about six experiences that empirical analysis identified as the strongest discriminators between bipolar I and major depressive disorder. The items cover two domains:
| Score (Number of "Yes" Items) | Interpretation |
|---|---|
| 0–2 | Lower likelihood of bipolar I — major depressive disorder more likely |
| 3 | Elevated likelihood — clinical correlation advised; sensitivity ~97% at this threshold |
| 4 or more | Positive screen — high likelihood of bipolar I; warrants structured diagnostic interview |
The recommended cutoff of four endorsed items maximizes the balance of sensitivity (0.88) and specificity (0.80) reported in the validation study. A positive RMS screen is not a diagnosis — it indicates that a structured diagnostic interview for bipolar disorder is warranted before treatment decisions are made.
Delivering the RMS digitally gives clinicians a structured bipolar I signal at the point of care. Automatic scoring and flagging calculate the total instantly and surface positive screens for clinician review. Longitudinal tracking stores results alongside PHQ-9 scores so changes in mood presentation become visible over time. Pre-visit SMS and email delivery ensures the screener is complete before the encounter, and EHR integration routes results into the chart without manual transcription. All data is captured in HIPAA-compliant infrastructure.
Routine RMS administration supports defensible documentation that a clinician considered bipolarity before prescribing antidepressant monotherapy — an increasingly relevant standard of care in depression management. Digital records of screening, scoring, and clinical follow-up provide an audit trail for quality reporting, payer audits, and risk management.
What does the Rapid Mood Screener detect?
The RMS is designed to identify patients with depressive symptoms who are likely to have bipolar I disorder rather than major depressive disorder. It is administered to help clinicians make this differential before initiating antidepressant treatment.
What is a positive RMS score?
Endorsing four or more of the six items is considered a positive screen, with sensitivity of 0.88 and specificity of 0.80 for bipolar I in the original validation. A score of three is sometimes used as a higher-sensitivity threshold when missed bipolarity carries greater risk.
How does the RMS differ from the MDQ?
The MDQ is a 15-item lifetime mania screener applicable to general populations, while the RMS is a 6-item tool optimized for patients already presenting with depression and incorporates depression-history features alongside manic-symptom items.
How long does the RMS take to complete?
Most patients complete the RMS in under two minutes. Its brevity is one of its core advantages over longer screeners, particularly in primary care and telehealth settings where visit time is limited.
Can the RMS diagnose bipolar I disorder?
No. The RMS is a screening instrument and not a diagnostic tool. A positive screen warrants a structured clinical interview using DSM criteria before any diagnostic or treatment decisions are made.
When should the RMS be used in primary care?
It is most useful when evaluating any patient with a depressive episode, particularly those with treatment-resistant depression, early age of onset, recurrent episodes, or a family history of bipolar disorder — situations where unrecognized bipolarity is more likely.
Last updated: May 2026.
The leading patient intake platform. HIPAA compliant forms for healthcare providers and organizations. Find out what you're missing!
